Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.77 |
| ▸ | HTR3B | O95264 | 3/20 | 0.77 |
| ▸ | HTR3A | P46098 | 3/20 | 0.77 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.77 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.77 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | ACR | P10323 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL2910175 | 0.89 | HTR3E (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5243029 | 0.88 | HTR3E (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6980748 | 0.84 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL7002143 | 0.79 | HTR3E (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL2913167 | 0.78 | HTR3E (0.79) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6953528 | 0.77 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL3860675 | 0.76 | TDP1 (0.55) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL7804174 | 0.76 | HTR3E (0.63) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL7240334 | 0.76 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6034777 | 0.75 | PLAU (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-6552029-B1 | For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis | CELLTECH R&D LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| EP-0934304-B1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| US-6114333-A | 2-Pyrimidineamine derivatives and processes for their preparation | CELLTECH THERAPEUTICS LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| EP-0934304-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998018782-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | HTR3E 1499/4885HTR3B 1512/4885HTR3A 664/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | HTR3E 1249/4885HTR3B 1267/4885HTR3A 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.